Explore All Access
Check if your research matches the topics covered in Antibody Therapeutics?
- Degree of match
- Common matching concepts
- Additional journal recommendations
Antibody Therapeutics : Impact Factor & More
eISSN: 2516-4236
Open AccessShare this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Antibody Therapeutics Key Metrics
CiteScore 
5
SJR
Q3Immunology
Time to Publish
View Chart Mo
Time to Publish
Sign up now and unlock a detailed chart of Time to publish for this journal
% of papers by time taken from submission to publication
0 to 3 months58%
4 to 6 months38%
7 to 9 months0%
Above 9 months4%
Did you find this useful?
Topics Covered on Antibody Therapeutics
Tumor microenvironment
Antibody-drug conjugate
Downstream processing
Blocking antibody
Augmented reality
Chimeric antigen receptor
Severe acute respiratory syndrome coronavirus
Neutralizing antibody
Angiotensin-converting enzyme
Human papillomavirus
Bispecific antibody
Antiserum
Pandemic
Human papillomavirus vaccination
Monoclonal antibody
Tumor targeting
Immune checkpoint inhibitors
Affinity maturation
Antibody Therapeutics Journal Specifications
Indexed in the following public directories
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | Oxford University Press |
| Language | English |
| Article Processing Charges | GBP 1750 | USD 2625 |
| Publication Time | 8 |
| Editorial Review Process | Blind peer review |
| General Details | |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Antibody Therapeutics ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Antibody Therapeutics
Beyond ADCs: Harnessing Bispecific Antibodies to Directly Induce Apoptosis for Targeted Tumor Eradication
- 29 Oct 2024
- Antibody Therapeutics
Leveraging High-Throughput Analytics and Automation to Rapidly Develop High-Concentration mAb Formulations: Integrated Excipient Compatibility and Viscosity Screening
- 12 Oct 2024
- Antibody Therapeutics
Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-phage-to-yeast (H2PtY) platform
- 10 Oct 2024
- Antibody Therapeutics
AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains.
- 26 Sep 2024
- Antibody therapeutics
Directed protein engineering identifies a human TIM-4 blocking antibody that enhances anti-tumor response to checkpoint inhibition in murine colon carcinoma
- 23 Sep 2024
- Antibody Therapeutics
FcRider: a recombinant Fc nanoparticle with endogenous adjuvant activities for hybrid immunization.
- 6 Sep 2024
- Antibody therapeutics
Beyond ADCs: Harnessing Bispecific Antibodies to Directly Induce Apoptosis for Targeted Tumor Eradication
- 29 Oct 2024
- Antibody Therapeutics
Leveraging High-Throughput Analytics and Automation to Rapidly Develop High-Concentration mAb Formulations: Integrated Excipient Compatibility and Viscosity Screening
- 12 Oct 2024
- Antibody Therapeutics
Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-phage-to-yeast (H2PtY) platform
- 10 Oct 2024
- Antibody Therapeutics
AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains.
- 26 Sep 2024
- Antibody therapeutics
Directed protein engineering identifies a human TIM-4 blocking antibody that enhances anti-tumor response to checkpoint inhibition in murine colon carcinoma
- 23 Sep 2024
- Antibody Therapeutics
FcRider: a recombinant Fc nanoparticle with endogenous adjuvant activities for hybrid immunization.
- 6 Sep 2024
- Antibody therapeutics
Compare Similar Journals with Antibody Therapeutics
Select Journals to Compare with Antibody Therapeutics
Total journals - 8
You can select up to 3 Journals at a time
Frontiers in Immunology
Publisher: FRONTIERS MEDIA SA
Scientific Reports
Publisher: NATURE PORTFOLIO
International Journal of Molecular Sciences
Publisher: MDPI
mAbs
Publisher: TAYLOR & FRANCIS INC
Antibodies
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
PLoS ONE
Publisher: PUBLIC LIBRARY SCIENCE
Nature Communications
Publisher: NATURE PORTFOLIO
Journal for ImmunoTherapy of Cancer
Publisher: BMJ PUBLISHING GROUP
0 Journals Selected to compare with
Antibody Therapeutics
Compare journals across 7 parameters SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
Get detailed Journal comparison report on your email by signing up
FAQs on Antibody Therapeutics
How many articles did Antibody Therapeutics publish last year? 
In 2023, Antibody Therapeutics publsihed 57 articles.
What is Citescore for Antibody Therapeutics?
Citescore for Antibody Therapeutics is 5.
What is the SJR for Antibody Therapeutics?
SJR for Antibody Therapeutics is Q3.
Who is the publisher of Antibody Therapeutics?
Oxford University Press is the publisher of Antibody Therapeutics.
